Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ribavirin · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks) | EXPERIMENTAL | Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks). |
| TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks) | EXPERIMENTAL | Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks). |
| TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks) | EXPERIMENTAL | Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks). |
| TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks) | ACTIVE_COMPARATOR | Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks). |
| Crossover Period 1 | EXPERIMENTAL | - |
| Crossover Period 2 | EXPERIMENTAL | - |
| Crossover Period 3 | EXPERIMENTAL | - |
| Crossover Period 4 | EXPERIMENTAL | - |
| Ribavirin capsule arm | ACTIVE_COMPARATOR | - |
| Ribavirin tablet arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ribavirin | DRUG | Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks. |
| Mericitabine | DRUG | Participants will receive mericitabine 1000 mg orally twice daily. |
| Peginterferon Alfa-2a | DRUG | Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly. |
| Placebo | DRUG | Participants will receive placebo matching to mericitabine orally twice daily. |
| Telaprevir | DRUG | Participants will receive telaprevir 750 mg orally three times daily. |
| ribavirin [Copegus] | DRUG | tablet under fed condition |
| ribavirin [Vilona] | DRUG | Single oral dose of a 400 mg capsule |
Inclusion Criteria: * Chronic hepatitis C infection for at least 6 months duration * Hepatitis C genotype 1a or 1b * Participants must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study * Participants showed a previous null response to therapy as defin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
High ribavirin dose is used for the treatment of chronic hepatitis C. It is an investigational small molecule being studied in Phase 2 clinical trials for this infectious disease. The drug is being developed by Roche Holding AG (RHHBY).
High ribavirin dose is a small molecule antiviral. While the exact mechanism is not specified, ribavirin is known to interfere with viral RNA replication. It is being studied in combination with other antiviral agents for chronic hepatitis C.
High ribavirin dose is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is conducting clinical trials to evaluate the drug's safety and efficacy in patients with chronic hepatitis C.
High ribavirin dose is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, with a total enrollment of 80 participants.
High ribavirin dose has been studied in two completed Phase 2 trials: NCT00944684, which evaluated high dose ribavirin in chronic hepatitis C, and NCT01482390, which studied mericitabine in combination with telaprevir and peginterferon alfa-2a/ribavirin. Both trials are completed.
High ribavirin dose refers to a higher dose of ribavirin, an antiviral medication. It is not a distinct drug but a dosing strategy. The trials listed include studies of ribavirin at higher doses, such as NCT00944684, which specifically investigated high dose ribavirin.